Integra LifeSciences (NSDQ:IART) shares ticked up today on fourth-quarter results that revealed mixed results when compared to the consensus forecast but resulted in raised guidance for fiscal 2020.
The Plainsboro, N.J.-based surgical devices company posted profits of $15.3 million, or 18¢ per share, on sales of $395.1 million for the three months ended Dec. 31, 2019, for a 39.1% bottom-line slide on sales growth of 3.1%.
Adjusted to exclude one-time items, earnings per share were 68¢, 1¢ ahead of Wall Street, where analysts were looking for sales of $397.5 million.
Integra LifeSciences said it now expects to log adjusted EPS of between $3.00 and $3.05, compared with $2.70 to $2.75 previously, and updated its prior sales guidance for between $1.55 billion to $1.57 billion, up from the previously projected range of $1.517 billion to $1.522 billion.
IART shares were up 3% at $60.59 per share in early-morning trading today.